Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Deruxtecan in TNBC-LAR with Low HER2
NCT05953168Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Aug 2023
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trastuzumab deruxtecan in triple-negative breast cancer (TNBC), sponsored by Fudan University. Planned start Aug 2023; status: not yet recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05953168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05953168.